Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...

Bristol Myers wins US FDA approval for new type of schizophrenia drug Healthcare & Pharmaceuticalscategory· September 27, 2024 2seventy bio will discontinue enrolling patients in a late-stage ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy ... In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults ...

2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults PRINCETON, N.J., September 15, 2024--Bristol Myers Squibb ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

(Bristol Myers Squibb via AP) Some people who took a new schizophrenia drug for a year ... of a cumbersome blood testing program. The FDA started the blood tests to watch for the risk of severe ...